weight loss on glp-1 Agonists Drugs Market Report, 2025-2030 Debunking GLP-1 Myths: The Truth

Record the fill volume, the resulting concentration and the reconstitution date on the vial label

Yammine, L., Balderas, J

It was developed by Eli Lilly and entered the published Phase 2 program in 2023 with three parallel disease contexts: obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease

The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release